{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:15:44Z","timestamp":1759882544361,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA033211"],"award-info":[{"award-number":["R25DA033211"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.drugalcdep.2022.109707","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T11:07:21Z","timestamp":1668856041000},"page":"109707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study"],"prefix":"10.1016","volume":"241","author":[{"given":"Kenneth L.","family":"Morford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette M.","family":"Tetrault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brynna","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Jennifer","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Declan T.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Madden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.drugalcdep.2022.109707_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10550880802122620","article-title":"The impact of benzodiazepine use on methadone maintenance treatment outcomes","volume":"27","author":"Brands","year":"2008","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.drugalcdep.2022.109707_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-244X-11-90","article-title":"Benzodiazepine use and misuse among patients in a methadone program","volume":"11","author":"Chen","year":"2011","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109707_bib3","first-page":"85","article-title":"Cohort study of the impact of high-dose opioid analgesics on overdose mortality","volume":"17","author":"Dasgupta","year":"2016","journal-title":"Pain. Med."},{"issue":"3","key":"10.1016\/j.drugalcdep.2022.109707_bib4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/ADM.0000000000000476","article-title":"Evaluating the impact of prescribed versus nonprescribed benzodiazepine use in methadone maintenance therapy: results from a population-based retrospective cohort study","volume":"13","author":"Eibl","year":"2019","journal-title":"J. Addict. Med."},{"issue":"3","key":"10.1016\/j.drugalcdep.2022.109707_bib5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11414-006-9025-3","article-title":"Reliability and validity of the BASIS-24 Mental Health Survey for Whites, African-Americans, and Latinos","volume":"33","author":"Eisen","year":"2006","journal-title":"J. Behav. Health Serv. Res."},{"key":"10.1016\/j.drugalcdep.2022.109707_bib6","unstructured":"FDA, (2016). FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. U.S. Food and Drug Administration. \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or\u3009."},{"key":"10.1016\/j.drugalcdep.2022.109707_bib7","unstructured":"FDA, (2017). FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. U.S. Food and Drug Administration. \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-urges-caution-about-withholding-opioid-addiction-medications\u3009."},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109707_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12954-017-0134-5","article-title":"The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario","volume":"14","author":"Franklyn","year":"2017","journal-title":"Harm Reduct. J."},{"issue":"1\u20132","key":"10.1016\/j.drugalcdep.2022.109707_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0376-8716(98)00175-6","article-title":"Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic","volume":"55","author":"Gelkopf","year":"1999","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109707_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.drugalcdep.2022.109707_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0740-5472(03)00130-2","article-title":"Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS","volume":"25","author":"Hubbard","year":"2003","journal-title":"J. Subst. Abus. Treat."},{"issue":"3","key":"10.1016\/j.drugalcdep.2022.109707_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0376-8716(93)90090-D","article-title":"Benzodiazepine and sedative use\/abuse by methadone maintenance clients","volume":"32","author":"Iguchi","year":"1993","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.drugalcdep.2022.109707_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","article-title":"Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines","volume":"49","author":"Jones","year":"2015","journal-title":"Am. J. Prev. Med."},{"issue":"1\u20132","key":"10.1016\/j.drugalcdep.2022.109707_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: a review of opioid and benzodiazepine combination use","volume":"125","author":"Jones","year":"2012","journal-title":"Drug Alcohol Depend."},{"issue":"7","key":"10.1016\/j.drugalcdep.2022.109707_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18223","article-title":"Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada","volume":"4","author":"Joudrey","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109707_bib16","first-page":"33","article-title":"Urine drug tests: ordering and interpreting results","volume":"99","author":"Kale","year":"2019","journal-title":"Am. Fam. Physician"},{"issue":"3","key":"10.1016\/j.drugalcdep.2022.109707_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1300\/J069v25n03_03","article-title":"Adolescent and young adult heroin patients: drug use and success in methadone maintenance treatment","volume":"25","author":"Kellogg","year":"2006","journal-title":"J. Addict. Dis."},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109707_bib18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13643-021-01764-9","article-title":"Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials","volume":"10","author":"Klimas","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2022.109707_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","article-title":"Opioid substitution therapy: Lowering the treatment thresholds","volume":"161","author":"Kourounis","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2022.109707_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings","volume":"126","author":"Krawczyk","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"issue":"11","key":"10.1016\/j.drugalcdep.2022.109707_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002965","article-title":"Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records","volume":"16","author":"Macleod","year":"2019","journal-title":"PLoS Med."},{"issue":"8","key":"10.1016\/j.drugalcdep.2022.109707_bib22","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1111\/add.14198","article-title":"An investigation of an open-access model for scaling up methadone maintenance treatment","volume":"113","author":"Madden","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2022.109707_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2698","article-title":"Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study","volume":"350","author":"Park","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.drugalcdep.2022.109707_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.drugalcdep.2005.09.004","article-title":"Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel","volume":"82","author":"Peles","year":"2006","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.drugalcdep.2022.109707_bib25","first-page":"285","article-title":"Benzodiazepine usage during 19.5 years in methadone maintenance treatment patients and its relation to long-term outcome","volume":"51","author":"Peles","year":"2014","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"issue":"2","key":"10.1016\/j.drugalcdep.2022.109707_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/ADM.0000000000000456","article-title":"Medication treatment with methadone or buprenorphine: differential reasons for premature discharge","volume":"13","author":"Proctor","year":"2019","journal-title":"J. Addict. Med."},{"issue":"3","key":"10.1016\/j.drugalcdep.2022.109707_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/02791072.2009.10400539","article-title":"Premature discharge from methadone treatment: patient perspectives","volume":"41","author":"Reisinger","year":"2009","journal-title":"J. Psychoact. Drugs"},{"issue":"10","key":"10.1016\/j.drugalcdep.2022.109707_bib28","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.addbeh.2007.01.010","article-title":"Retention and illicit drug use among methadone patients in Israel: a gender comparison","volume":"32","author":"Schiff","year":"2007","journal-title":"Addict. Behav."},{"issue":"8","key":"10.1016\/j.drugalcdep.2022.109707_bib29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/archpsyc.1981.01780330033003","article-title":"Treatment for drug abuse. Follow-up outcomes and length of time spent","volume":"38","author":"Simpson","year":"1981","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.drugalcdep.2022.109707_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0376-8716(81)90061-2","article-title":"Diazepam use among methadone maintenance patients: patterns and dosages","volume":"8","author":"Stitzer","year":"1981","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109707_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"J. Addict. Dis."},{"issue":"1","key":"10.1016\/j.drugalcdep.2022.109707_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0376-8716(96)01230-6","article-title":"Retention in a low-threshold methadone maintenance program","volume":"41","author":"Torrens","year":"1996","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.drugalcdep.2022.109707_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.drugalcdep.2005.11.020","article-title":"Predictors of retention in methadone programs: a signal detection analysis","volume":"83","author":"Villafranca","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2022.109707_bib34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.addbeh.2018.08.010","article-title":"Nonmedical prescription sedative\/tranquilizer use in alcohol and opioid use disorders","volume":"88","author":"Votaw","year":"2019","journal-title":"Addict. Behav."},{"issue":"2","key":"10.1016\/j.drugalcdep.2022.109707_bib35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/02791072.2014.901587","article-title":"Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention","volume":"46","author":"White","year":"2014","journal-title":"J. Psychoact. Drugs"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871622004446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871622004446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:27:24Z","timestamp":1759829244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871622004446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":35,"alternative-id":["S0376871622004446"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109707","relation":{},"ISSN":["0376-8716"],"issn-type":[{"type":"print","value":"0376-8716"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109707"}}